Harmony Biosciences Holdings, Inc. (HRMY)
- Previous Close
31.70 - Open
31.81 - Bid 31.23 x 200
- Ask 31.36 x 100
- Day's Range
31.26 - 31.81 - 52 Week Range
18.61 - 39.26 - Volume
314,242 - Avg. Volume
429,501 - Market Cap (intraday)
1.776B - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
13.48 - EPS (TTM)
2.32 - Earnings Date Jul 30, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
42.25
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
www.harmonybiosciences.comRecent News: HRMY
Performance Overview: HRMY
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HRMY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HRMY
Valuation Measures
Market Cap
1.78B
Enterprise Value
1.59B
Trailing P/E
13.48
Forward P/E
21.55
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.01
Price/Book (mrq)
3.45
Enterprise Value/Revenue
2.58
Enterprise Value/EBITDA
6.80
Financial Highlights
Profitability and Income Statement
Profit Margin
22.30%
Return on Assets (ttm)
16.30%
Return on Equity (ttm)
28.73%
Revenue (ttm)
617.51M
Net Income Avi to Common (ttm)
137.7M
Diluted EPS (ttm)
2.32
Balance Sheet and Cash Flow
Total Cash (mrq)
372.35M
Total Debt/Equity (mrq)
37.46%
Levered Free Cash Flow (ttm)
202.42M
Research Analysis: HRMY
Company Insights: HRMY
HRMY does not have Company Insights